The XIV Day of Infectious Diseases hosted by the Spanish Society of Internal Medicine (SEMI) kicked off with a focus on therapeutic advancements in treating resistant infections and HIV. Experts discussed the need for new antibiotics to combat resistant gram-negative and gram-positive infections, as well as the simplification of HIV treatment.
Juan Pablo Horcajada from the Hospital del Mar in Barcelona addressed the treatment of resistant gram-negative infections, emphasizing the need for more evidence to determine the effectiveness of new treatments. The discussion included potential drugs for treating Pseudomonas aeruginosa, carbapenemase-producing Enterobacteriaceae, and Acinetobacter baumannii.
Jaime Lora-Tamayo from the 12 de Octubre University Hospital in Madrid presented on the treatment of resistant gram-positive infections, focusing on MRSA and Enterococcus. He highlighted new cephalosporins with anti-MRSA activity and long-acting glycopeptides as therapeutic alternatives.
Carlos Duenas from the University Clinical Hospital of Valladolid provided an update on HIV treatment in Spain. He stressed the importance of individualizing treatment plans and discussed future simplification treatments like islatravir and Lenacapavor + 2bNAns.
While the experts are hopeful about the future of infectious disease treatment, they acknowledge the need for more scientific evidence to fully establish the effectiveness of new therapies. It is recommended that readers consult healthcare professionals for any health-related questions.